IPEMA

CFTR corrector and potentiator

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

IPEMA is an experimental substance used in studies and not yet available as a human pharmaceutical. It was created as a derivate of a triple-acting compound TMA, which shows anti-inflammatory activity in addition to CFTR corrector and potentiator properties, but is mutagenic. In relation to cystic fibrosis, our AIM tool found the data that IPEMA can be effective in both correcting F508del-CFTR and potentiating CFTR-dependent chloride transport in G551D mutants.

Synonyms

4-isopropyl-6-ethyl-4′-methylangelicin

Marketed as

N/A

Dietary sources

N/A

Structure image not available

N/A

Drug-Mutation Relation

results for D1152H / F508del

See all data on IPEMA

Treats

Mutation	Link	Tested on	Impact factor	Notes
F508del	Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators	human cell cultures	3.85	Less effective than TMA or lumacaftor.

Does not treat

Mutation	Link	Tested on	Impact factor	Notes